Corporate welfare and drugs companies
17/02/16 12:46
The cost of drugs and other medical equipment is of growing concern to both public health systems and private health insurance companies. Regarding the former, pharmaceutical companies can push up the price of drugs in order to artificially boost taxpayer-funded profits.
The most recent example of this has been the case of Martin Shkreli who acquired, and dramatically increased the cost of Daraprim, an anti-malarial drug. After taking over the company, the price of the drug in the US was increased by over 5,000% overnight – from $13.50 to $750 a pill.
Leave a Reply
You must be logged in to post a comment.